The use of noninvasive brain stimulation techniques in autism spectrum disorder.
Hold off recommending rTMS or tDCS for kids with ASD until larger, rigorous pediatric trials are published.
01Research in Context
What this study did
Andrews et al. (2024) looked at every paper that tested non-invasive brain stimulation on people with autism. These tools are rTMS and tDCS—magnets or mild electric currents on the scalp. The team read all the small trials and wrote a plain-language summary.
They did not run a new experiment. They simply judged how strong the proof is today.
What they found
The evidence is still early. No large, careful study shows clear benefit for kids with ASD. The authors say wait—do not offer these tools outside of research.
Off-label use in children is not yet safe or fair to families.
How this fits with other research
Trembath et al. (2023) reached the same verdict for every non-drug therapy: no single method helps every child. Their wide map includes the weak NIBS trials M et al. now highlight.
Hirota et al. (2014) saw the same empty shelf for antiepileptic drugs—seven small RCTs, no clear win. The pattern repeats: small samples, hopeful idea, no solid proof.
Tan et al. (2021) told us probiotics also lack strong RCTs. Across topics—gut bugs, magnets, or pills—the field keeps crying for bigger, tougher studies first.
Why it matters
You may get parent questions about “brain zaps” after news headlines. Show them this review: science has not crossed the finish line. Keep your treatment plan anchored in tools with real backing—like EIBI or parent-mediated ABA—while you wait for larger pediatric trials.
Get CEUs on This Topic — Free
The ABA Clubhouse has 60+ on-demand CEUs including ethics, supervision, and clinical topics like this one. Plus a new live CEU every Wednesday.
Add a one-page handout in your intake folder that says “NIBS for autism—still experimental” and list evidence-based options families can use today.
02At a glance
03Original abstract
Noninvasive brain stimulation (NIBS) techniques, including repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), have recently emerged as alternative, nonpharmacological interventions for a variety of psychiatric, neurological, and neurodevelopmental conditions. NIBS is beginning to be applied in both research and clinical settings for the treatment of core and associated symptoms of autism spectrum disorder (ASD) including social communication deficits, restricted and repetitive behaviors, irritability, hyperactivity, depression and impairments in executive functioning and sensorimotor integration. Though there is much promise for these targeted device-based interventions, in other disorders (including adult major depressive disorder (MDD) and obsessive compulsive disorder (OCD) where rTMS is FDA cleared), data on the safety and efficacy of these interventions in individuals with ASD is limited especially in younger children when neurodevelopmental interventions typically begin. Most studies are open-label, small scale, and/or focused on a restricted subgroup of individuals with ASD. There is a need for larger, randomized controlled trials that incorporate neuroimaging in order to develop predictive biomarkers of treatment response and optimize treatment parameters. We contend that until such studies are conducted, we do not have adequate estimates of the safety and efficacy of NIBS interventions in children across the spectrum. Thus, broad off-label use of these techniques in this population is not supported by currently available evidence. Here we discuss the existing data on the use of NIBS to treat symptoms related to ASD and discuss future directions for the field.
Autism research : official journal of the International Society for Autism Research, 2024 · doi:10.1016/j.brs.2017.11.016